The Cooper Companies, Inc.

$19.00

SKU: COO Category:

Description

The Cooper Companies delivered a mixed result in Q4, with revenues above market expectations, but it failed to surpass the analyst consensus in terms of earnings. The company achieved significant revenues, nearing $3.6 billion. CooperVision’s outstanding performance stands out, achieving an impressive 11th consecutive quarter of double-digit organic growth. At the same time, CooperSurgical set quarterly revenues high, propelled by its fertility business securing a 12th consecutive quarter of double-digit organic growth. CooperVision’s MyDay series continues to spearhead growth, demonstrating exceptional satisfaction rates and receiving accolades for innovation. MyDay Toric and MyDay Energys have maintained strong demand. MiSight’s impressive 41% revenue growth in myopia management, driven by positive trends in the Americas and EMEA, solidifies Cooper’s position in proactive myopia control. Cooper’s team envisions a healthy contact lens market, expecting continued growth amid global trends in myopia prevalence. Beyond contact lenses, CooperSurgical’s diverse portfolio, including fertility solutions and medical devices, positions the company as a prominent player in addressing global reproductive health challenges. Besides, the company added a few Cook Medical assets to CooperSurgical’s Medical Device Portfolio. Revenues from this acquisition may increase by 5% to 7% in constant currency over Cooper’s fiscal year 2024.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!